Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhaled liposomal amikacin.

Valerie Waters1, Felix Ratjen

  • 1Division of Infectious Diseases, Department of Pediatrics, Hospital for Sick Children, University of Toronto 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.

Expert Review of Respiratory Medicine
|June 3, 2014
PubMed
Summary

Arikace, an inhaled liposomal amikacin formulation, shows promise for treating cystic fibrosis lung infections. Clinical trials indicate it is safe and improves lung function, comparable to existing treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A 3-Year-Old Girl With a Chest Wall Mass.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ≥2 years with cystic fibrosis: 96-week interim results from a phase 3 open-label extension study.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

Post-infectious bronchiolitis obliterans in children: pathogenesis, treatment strategies, and future directions.

Current opinion in pediatrics·2026
Same author

Automated Ultrashort Echo Time (UTE) MRI Low Signal Volume Analysis in Stable Pediatric Cystic Fibrosis and After Elexacaftor/Tezacaftor/Ivacaftor Therapy.

Journal of magnetic resonance imaging : JMRI·2026
Same author

Real-world impact of elexacaftor/tezacaftor/ivacaftor on health-related quality of life in adults with cystic fibrosis: A 12-month multicenter cohort study.

Respiratory medicine·2026
Same author

The Impact of Nutritional Status on Lung Function Trajectories in Pediatric Patients With Primary Ciliary Dyskinesia.

Pediatric pulmonology·2026

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Cystic Fibrosis (CF) patients often suffer from chronic Pseudomonas aeruginosa infections.
  • Effective delivery of antibiotics to biofilms and airway secretions in CF lungs remains a challenge.
  • Amikacin is an aminoglycoside antibiotic with activity against P. aeruginosa.

Purpose of the Study:

  • To evaluate the safety and efficacy of Arikace™, an inhaled liposomal amikacin formulation, for CF pulmonary infections.
  • To compare Arikace™ to tobramycin inhalation solution in CF patients.
  • To explore potential applications of Arikace™ in other difficult-to-treat lung infections.

Main Methods:

  • Phase I, II, and III clinical trials were conducted in CF patients with chronic P. aeruginosa infections.
Keywords:
amikacinclinical trialcystic fibrosisinhalationpseudomonas

Related Experiment Videos

  • Studies involved administration of inhaled liposomal amikacin (Arikace™).
  • Lung function was assessed, including forced expiratory volume in 1 second (FEV1).

    • Main Results:

    • Phase I and II studies demonstrated Arikace™ safety and significant lung function improvements after 14-28 days.
    • Phase III trials showed Arikace™ achieved comparable lung function increases to tobramycin inhalation solution.
    • A Phase II trial is ongoing for nontuberculous mycobacterial lung disease.

    Conclusions:

    • Inhaled liposomal amikacin (Arikace™) is a safe and effective option for CF patients with P. aeruginosa infections.
    • Arikace™ demonstrates comparable efficacy to tobramycin inhalation solution.
    • Arikace™ holds potential for treating other challenging pulmonary infections, including nontuberculous mycobacterial disease.